Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Bluebird Takes Flight On Very Promising, Very Early Data

Investors have had good reason to be skeptical of Bluebird Bio (NASDAQ:BLUE). Gene therapy was the "next big thing" in the mid-to-late 1990s and while it is too negative to say it has thus far produced almost nothing of value, it certainly hasn't lived up to "the medicine of tomorrow, today!"...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.